Drug Patents owned by Sun Pharm

1. List of Absorica Ld drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750711 SUN PHARM Low dose oral pharmaceutical composition of isotretinoin
May, 2035

(12 years from now)

US9700535 SUN PHARM Oral pharmaceutical composition of isotretinoin
Aug, 2035

(12 years from now)

Drugs and Companies using ISOTRETINOIN ingredient

Market Authorisation Date: 05 November, 2019

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

2. List of Bromsite drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778999 SUN PHARM Non-steroidal anti-inflammatory ophthalmic compositions
Aug, 2029

(6 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 08 April, 2016

Treatment: Treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of BROMSITE before it's patent expiration?
More Information on Dosage

3. List of Cequa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(10 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(10 years from now)

US9937225 SUN PHARM Topical formulations and uses thereof
Aug, 2033

(10 years from now)

US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(14 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 14 August, 2018

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

4. List of Drizalma Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413525 SUN PHARM Duloxetine sprinkles
Apr, 2037

(14 years from now)

US11202772 SUN PHARM Duloxetine sprinkles
Apr, 2037

(14 years from now)

US10959982 SUN PHARM Duloxetine sprinkles
Apr, 2037

(14 years from now)

US9839626 SUN PHARM Duloxetine sprinkles
Apr, 2037

(14 years from now)

Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 July, 2019

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

More Information on Dosage

5. List of Ezallor Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10413543 SUN PHARM Stable multiparticulate pharmaceutical composition of rosuvastatin
Feb, 2036

(13 years from now)

Drugs and Companies using ROSUVASTATIN CALCIUM ingredient

Market Authorisation Date: 18 December, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

6. List of Infugem drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(10 years from now)

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

7. List of Odomzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178563 SUN PHARM Compounds and compositions as hedgehog pathway modulators
Jul, 2029

(6 years from now)

US8063043 SUN PHARM Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
Sep, 2029

(6 years from now)

US10266523 SUN PHARM Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Mar, 2036

(13 years from now)

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of basal cell carcinoma

Dosage: CAPSULE;ORAL

More Information on Dosage

8. List of Riomet Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962336 SUN PHARM Extended release suspension compositions
May, 2035

(12 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2019

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

9. List of Winlevi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2023

(15 days ago)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(5 months from now)

US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(5 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2028

(5 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Aug, 2028

(5 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Nov, 2028

(5 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Feb, 2029

(6 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

NCE-1 date: August, 2024

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage

10. List of Xelpros drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539262 SUN PHARM Ophthalmic composition comprising a prostaglandin
Oct, 2028

(5 years from now)

US9629852 SUN PHARM Ophthalmic composition comprising a prostaglandin
Sep, 2029

(6 years from now)

Drugs and Companies using LATANOPROST ingredient

Market Authorisation Date: 12 September, 2018

Treatment: Reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage

11. List of Yonsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144 SUN PHARM Abiraterone acetate formulation and methods of use
Mar, 2034

(11 years from now)

US10292990 SUN PHARM Abiraterone steroid formulation
May, 2034

(11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Market Authorisation Date: 22 May, 2018

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

How can I launch a generic of YONSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in